Neuraxis (NRXS) Interest Coverage Ratio (2022 - 2025)
Neuraxis (NRXS) posted Interest Coverage Ratio of 51.28 for Q4 2025, up 172.43% sequentially from 70.8 in Q3 2025, and up 382.9% YoY from 10.62 in Q4 2024.
Neuraxis (NRXS) Interest Coverage Ratio (2022 - 2025) Analysis & Trends
Neuraxis has reported Interest Coverage Ratio for 4 years, with the latest figure at 51.28 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 382.9% year-over-year to 51.28 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 101.36 (up 850.7% YoY) and the FY2025 annual result came in at 21.68, down 75.79% from the prior year.
- Interest Coverage Ratio improved to 51.28 in Q4 2025 per NRXS's latest filing, from 70.8 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 51.28 in Q4 2025 and troughed at 1205.05 in Q4 2023.
- A 4-year average of 162.58 and a median of 19.44 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio tumbled 4969.59% in 2023, then soared 382.9% in 2025.
- Over 4 years, Interest Coverage Ratio stood at 23.77 in 2022, then slumped by 4969.59% to 1205.05 in 2023, then jumped by 100.88% to 10.62 in 2024, then jumped by 382.9% to 51.28 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 51.28, 70.8, and 4.59 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.28 |
| Sep 30, 2025 | -70.80 |
| Jun 30, 2025 | -4.59 |
| Mar 31, 2025 | -1,025.97 |
| Dec 31, 2024 | 10.62 |
| Sep 30, 2024 | -25.53 |
| Jun 30, 2024 | -3.83 |
| Mar 31, 2024 | -68.98 |
| Dec 31, 2023 | -1,205.05 |
| Sep 30, 2023 | -29.45 |
| Jun 30, 2023 | -5.74 |
| Mar 31, 2023 | -5.54 |
| Dec 31, 2022 | -23.77 |
| Sep 30, 2022 | -11.94 |
| Jun 30, 2022 | -19.44 |